| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014702467 |
| P356 | DOI | 10.1038/CDDIS.2015.143 |
| P932 | PMC publication ID | 4669826 |
| P698 | PubMed publication ID | 26086967 |
| P5875 | ResearchGate publication ID | 278790376 |
| P50 | author | Klas Wiman | Q57419790 |
| P2093 | author name string | J Gullbo | |
| N Mohell | |||
| V J N Bykov | |||
| Å Fransson | |||
| A Hallberg | |||
| J Alfredsson | |||
| M Uustalu | |||
| S Byström | |||
| U Björklund | |||
| P2860 | cites work | DNA topoisomerases and their poisoning by anticancer and antibacterial drugs | Q28284744 |
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Cisplatin: mode of cytotoxic action and molecular basis of resistance | Q29615385 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction | Q29618515 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Clinical outcomes and correlates of TP53 mutations and cancer | Q33693838 | ||
| Pharmacological strategies for overcoming multidrug resistance | Q33997660 | ||
| Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Q34103978 | ||
| Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy | Q34159386 | ||
| The resurgence of platinum-based cancer chemotherapy | Q34649255 | ||
| Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). | Q34750366 | ||
| Molecular mechanisms of resistance and toxicity associated with platinating agents | Q35758048 | ||
| The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines | Q35993429 | ||
| Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo | Q36291188 | ||
| Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. | Q36895126 | ||
| High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis | Q36936167 | ||
| APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase | Q37577458 | ||
| P53 and its molecular basis to chemoresistance in breast cancer | Q37982133 | ||
| Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies | Q37998748 | ||
| P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. | Q38078058 | ||
| Role of glutathione in cancer progression and chemoresistance | Q38114436 | ||
| Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. | Q38175469 | ||
| Drugging the p53 pathway: understanding the route to clinical efficacy | Q38191796 | ||
| Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 | ||
| Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance | Q38855681 | ||
| PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines | Q38994024 | ||
| PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa | Q39096603 | ||
| PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo | Q39607175 | ||
| PRIMA-1 reactivates mutant p53 by covalent binding to the core domain | Q39857551 | ||
| Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches | Q40188405 | ||
| Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. | Q40401654 | ||
| Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding | Q41453979 | ||
| Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. | Q41518542 | ||
| Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. | Q42445479 | ||
| Synergistic interaction of anticancer agents: a cellular perspective | Q45065029 | ||
| Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. | Q45906744 | ||
| PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. | Q46458121 | ||
| Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. | Q46496853 | ||
| PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance | Q46868792 | ||
| Clinical studies of reversal of drug resistance based on glutathione | Q47785533 | ||
| Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. | Q52833956 | ||
| PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. | Q53867820 | ||
| PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. | Q53967886 | ||
| Role of glutathione in cisplatin resistance in osteosarcoma cell lines. | Q54076837 | ||
| Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. | Q55489964 | ||
| Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues | Q68922078 | ||
| Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice | Q69842539 | ||
| Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan | Q73929381 | ||
| Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients | Q77613965 | ||
| Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer | Q84959068 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| doxorubicin | Q18936 | ||
| ovarian cancer | Q172341 | ||
| P304 | page(s) | e1794 | |
| P577 | publication date | 2015-06-18 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells | |
| P478 | volume | 6 |
| Q37247680 | 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells |
| Q52579544 | APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. |
| Q91584678 | Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma |
| Q91259871 | An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient |
| Q64257608 | Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q92635727 | Ferroptosis in Cancer Cell Biology |
| Q92073835 | Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response |
| Q89292459 | Glutathione in Ovarian Cancer: A Double-Edged Sword |
| Q53691994 | Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. |
| Q92260021 | Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network |
| Q64115872 | Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers |
| Q37736385 | Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation |
| Q58714397 | Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 |
| Q89497311 | Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells |
| Q33844916 | Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells |
| Q33865098 | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events |
| Q53369992 | MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. |
| Q38746991 | Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? |
| Q49788157 | Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. |
| Q39438805 | Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer |
| Q47274927 | PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies |
| Q37641688 | PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation |
| Q64239929 | PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level |
| Q36738640 | PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells |
| Q64106699 | Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells |
| Q48211811 | Recent developments with rhodanine as a scaffold for drug discovery |
| Q90442948 | Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q41489534 | Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin |
| Q36904012 | Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q26766341 | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy |
| Q45301128 | The Cytotoxic Action of Cytochrome C/Cardiolipin Nanocomplex (Cyt-CL) on Cancer Cells in Culture |
| Q58761640 | The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells |
| Q91898958 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia |
| Q39218376 | Understanding cell cycle and cell death regulation provides novel weapons against human diseases. |
| Q38647100 | Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines |
| Q55002919 | p53 and metabolism: from mechanism to therapeutics. |
| Q92500329 | p53 as a hub in cellular redox regulation and therapeutic target in cancer |
Search more.